A Testimonial to Treating a Gene Involved in Metastatic Prostate Cancer
This linked article is an excellent personalized example of treating a man with metastatic prostate cancer and a mutated genetic defect in his BRCA2 gene. He was treated with the PARP inhibitor olaparib which is approved for ovarian cancer. The story itself needs little comment so I urge you to read the following link from the Prostate Cancer Foundation.
This entry was posted in 2017
. Bookmark the permalink